{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:09Z","timestamp":1791353769258,"version":"4.3.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T00:00:00Z","timestamp":1464998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12185-016-2039-6","type":"journal-article","created":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T06:23:11Z","timestamp":1465021391000},"page":"6-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Biology and clinical application of CAR T cells for B cell malignancies"],"prefix":"10.1007","volume":"104","author":[{"given":"Marco L.","family":"Davila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,4]]},"reference":[{"key":"2039_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev.immunol.25.022106.141548","volume":"25","author":"MA Williams","year":"2007","unstructured":"Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007;25:171\u201392.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2039_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri1330","volume":"4","author":"RT Abraham","year":"2004","unstructured":"Abraham RT, Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004;4(4):301\u20138.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2039_CR3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64(5):891\u2013901.","journal-title":"Cell"},{"issue":"7","key":"2039_CR4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/eji.1830210718","volume":"21","author":"PG Coulie","year":"1991","unstructured":"Coulie PG, Uyttenhove C, Wauters P, Manolios N, Klausner RD, Samelson LE, et al. Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. Eur J Immunol. 1991;21(7):1703\u20139.","journal-title":"Eur J Immunol"},{"issue":"5040","key":"2039_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.1532456","volume":"255","author":"F Letourneur","year":"1992","unstructured":"Letourneur F, Klausner RD. Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science. 1992;255(5040):79\u201382.","journal-title":"Science"},{"issue":"2","key":"2039_CR6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2039_CR7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/eji.1830230705","volume":"23","author":"T Brocker","year":"1993","unstructured":"Brocker T, Peter A, Traunecker A, Karjalainen K. New simplified molecular design for functional T cell receptor. Eur J Immunol. 1993;23(7):1435\u20139.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2039_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215\u201323.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"2039_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","volume":"1","author":"MC Gong","year":"1999","unstructured":"Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1(2):123\u20137.","journal-title":"Neoplasia"},{"issue":"5","key":"2039_CR10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653\u20139.","journal-title":"J Exp Med"},{"issue":"4","key":"2039_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188(4):619\u201326.","journal-title":"J Exp Med"},{"issue":"1","key":"2039_CR12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor. Nat Biotechnol. 2002;20(1):70\u20135.","journal-title":"Nat Biotechnol"},{"issue":"25","key":"2039_CR13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380.","journal-title":"N Engl J Med"},{"issue":"2","key":"2039_CR14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169\u201380.","journal-title":"J Immunother"},{"issue":"4","key":"2039_CR15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676\u201384.","journal-title":"Leukemia"},{"issue":"7","key":"2039_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ Stegen van der","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499\u2013509.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2039_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/cgt.2014.81","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang X, Riviere I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015;22(2):85\u201394.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"2039_CR18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2039_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"95","key":"2039_CR20","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2039_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CJI.0000000000000072","volume":"38","author":"X Wang","year":"2015","unstructured":"Wang X, Olszewska M, Qu J, Wasielewska T, Bartido S, Hermetet G, et al. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J Immunother. 2015;38(3):127\u201335.","journal-title":"J Immunother"},{"issue":"24","key":"2039_CR22","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJM200406103502422","volume":"350","author":"A Fischer","year":"2004","unstructured":"Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med. 2004;350(24):2526\u20137 (author reply 26\u20137).","journal-title":"N Engl J Med"},{"issue":"5644","key":"2039_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415\u20139.","journal-title":"Science"},{"issue":"Supplement","key":"2039_CR24","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S1525-0016(16)33083-0","volume":"24","author":"J Eyquem","year":"2016","unstructured":"Eyquem J, Mansilla-Soto J, Odak A, Sadelain M. ASGCT 2016 Meeting. Mol Ther. 2016;24(Supplement):S109.","journal-title":"Mol Ther."},{"issue":"5","key":"2039_CR25","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822\u20136.","journal-title":"J Clin Invest"},{"issue":"6","key":"2039_CR26","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261\u201371.","journal-title":"Blood"},{"issue":"18","key":"2039_CR27","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"8","key":"2039_CR28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"2039_CR29","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"20","key":"2039_CR30","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099\u2013102.","journal-title":"Blood"},{"issue":"3","key":"2039_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3):279\u201386.","journal-title":"Nat Med"},{"issue":"9","key":"2039_CR32","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"M Sadelain","year":"2015","unstructured":"Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125(9):3392\u2013400.","journal-title":"J Clin Invest"},{"issue":"9","key":"2039_CR33","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","volume":"1","author":"ML Davila","year":"2012","unstructured":"Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M. How do CARs work?: early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012;1(9):1577\u201383.","journal-title":"Oncoimmunology"},{"issue":"303","key":"2039_CR34","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2039_CR35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol."},{"issue":"21","key":"2039_CR36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood.V124.21.550.550","volume":"124","author":"JN Kochenderfer","year":"2014","unstructured":"Kochenderfer JN, Somerville R, Lu L, Iwamoto A, Yang JC, Klebanoff C, et al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. Blood. 2014;124(21):550.","journal-title":"Blood"},{"issue":"23","key":"2039_CR37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V126.23.184.184","volume":"126","author":"CJ Turtle","year":"2015","unstructured":"Turtle CJ, Berger C, Sommermeyer D, Hanafi L-A, Pender B, Robinson EM, et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood. 2015;126(23):184.","journal-title":"Blood"},{"issue":"23","key":"2039_CR38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","volume":"126","author":"SJ Schuster","year":"2015","unstructured":"Schuster SJ, Svoboda J, Dwivedy Nasta S, Porter DL, Chong EA, Landsburg DJ, et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):183.","journal-title":"Blood"},{"issue":"23","key":"2039_CR39","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood.V126.23.3991.3991","volume":"126","author":"FL Locke","year":"2015","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 clinical results of the ZUMA-1 (KTE-C19-101) study: a phase 1\u20132 multi-center study evaluating the safety and efficacy of anti-CD19 CAR T cells (KTE-C19) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL). Blood. 2015;126(23):3991.","journal-title":"Blood"},{"issue":"9","key":"2039_CR40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood"},{"issue":"4","key":"2039_CR41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"224","key":"2039_CR42","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med"},{"issue":"177","key":"2039_CR43","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"issue":"16","key":"2039_CR44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"16","key":"2039_CR45","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"9967","key":"2039_CR46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet."},{"issue":"7","key":"2039_CR47","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O\u2019Brien S, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86(7):1216\u201330.","journal-title":"Cancer"},{"issue":"12","key":"2039_CR48","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov."},{"issue":"1","key":"2039_CR49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71\u20135.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2039_CR50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"},{"issue":"26","key":"2039_CR51","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154\u20137.","journal-title":"Blood"},{"issue":"10","key":"2039_CR52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2039_CR53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"42","key":"2039_CR54","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.0505539102","volume":"102","author":"N Yazawa","year":"2005","unstructured":"Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA. 2005;102(42):15178\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"2039_CR55","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133\u201341.","journal-title":"Blood"},{"issue":"8","key":"2039_CR56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","volume":"61","author":"M Chmielewski","year":"2012","unstructured":"Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012;61(8):1269\u201377.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2039_CR57","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440\u20139.","journal-title":"Nat Med"},{"issue":"3\u20134","key":"2039_CR58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3\u20134):263\u201372.","journal-title":"Mol Immunol"},{"issue":"6","key":"2039_CR59","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578\u201390.","journal-title":"Cancer Res"},{"issue":"8","key":"2039_CR60","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","volume":"191","author":"C Ankri","year":"2013","unstructured":"Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol. 2013;191(8):4121\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"2039_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv146","volume":"107","author":"S Kobold","year":"2015","unstructured":"Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. 2015;107(8):1\u201310.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2039_CR62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43\u201353.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2039_CR63","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"},{"issue":"215","key":"2039_CR64","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2039-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2039-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2039-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T17:19:12Z","timestamp":1600708752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2039-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,4]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["2039"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2039-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,4]]}}}